SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.

Sacha I RothschildAlfred ZippeliusEric I EbouletSpasenija Savic PrinceDaniel BetticherAdrienne BettiniMartin FrühMarkus JoergerDidier LardinoisHans GelpkeLaetitia A MautiChristian BritschgiWalter WederSolange PetersMichael MarkRichard CathomasAdrian F OchsenbeinWolf-Dieter JanthurChristine WaibelNicolas MachPatrizia FroeschMartin BuessPierre BohanesGilles GodarCorinne RusterholzMichel GonzalezMiklos Plessnull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

The addition of perioperative durvalumab to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer is safe and exceeds historical data of chemotherapy alone with a high MPR and an encouraging 1-year EFS rate of 73%.

Keyphrases

neoadjuvant chemotherapy
locally advanced
rectal cancer
lymph node
sentinel lymph node
squamous cell carcinoma
radiation therapy
electronic health record
patients undergoing
cardiac surgery
big data
open label
clinical trial
machine learning
early stage
chemotherapy induced